✦ LIBER ✦

735 L-Leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): High dose (HD) versus low dose (LD)

✍ Scribed by R. Labianca; S. Cascinu; S. Barni; G. Fiorentini; L. Frontini; G. Comella; A. Zaniboni; G. Dallavalle; G. Pancera; A.C. Luporini; A. Pessi; G. Luporini

Book ID: 116167481
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 298 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95984-e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

358Early results of a large randomised t

358Early results of a large randomised trial of ‘tomudex’ (raltitrexed) versus 5-fluorouracil (5FU) plus high dose leucovorin (HDLV) in patients with advanced colorectal cancer (ACC)

✍ J.J. McAleer; G. Cocconi; G. van Hazel; E. Francois; J.Y. Douillard; K. Possinge 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Double alternate modulation of high dose

Double alternate modulation of high dose fluorouracil (5FU) by interferon alpha (IFNα) and phosphonacetyl-L-aspartic acid (pala) in patients with advanced colorectal cancer (ACC). A multicenter phase II study

✍ Punt, CJA; Burghouts, JThM; Kateman, I; Croles, JJ; Kamm, Y; De Mulder, PHM 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 160 KB

732 Modulation of weekly high dose infus

732 Modulation of weekly high dose infusional 5-fluorouracil (FU) by leucovorin (LV), α-interferon (IFN) or LV plus IFN in advanced colorectal cancer. Results of a multicenter randomized trial of the AIO

✍ C.H. Köhne; P. Schöffski; H. Wilke; C. Käufer; H. Rauschecker; R. Andreesen; U. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Modulation of 5-fluorouracil with methot

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-l-aspartate in patients with advanced colorectal cancer. Results of a phase II study

✍ C.-H. Köhne; A. Harstrick; W. Hiddemann; P. Schöffski; H. Wilke; C. Bokemeyer; B 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 550 KB

A phase II study of irinotecan (CPT-11)

A phase II study of irinotecan (CPT-11) alternated with a weekly schedule of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour infusion 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (MCRC)

✍ Rosati, G.; Tucci, A.; Rinaldi, A.; Colarusso, D.; Rossi, A.; Pizza, C.; Manzion 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB